A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...

Kamilia Smith, MD, FACOG, NCMP, discusses how identifying and effectively treating vasomotor symptoms (VMS) in menopausal women are hindered by diagnostic challenges, inadequate screening practices, ...

Living with Pulmonary Arterial Hypertension (PAH) affects not only patients but also the caregivers who support them, facing ...

Patients with systemic sclerosis who have lipodermatosclerosis vs those without lipodermatosclerosis have a higher rate of cardiac arrhythmia, heart failure, and pulmonary hypertension.

The oxygen-sensing protein HIF-1alpha may contribute to worsening pulmonary arterial hypertension (PAH) and is a possible ...

They highlighted the underrepresentation of minority groups in pulmonary arterial hypertension (PAH) trials, along with the ...

Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

I hope that, in the long-term, our technology will improve patient outcomes for this disease. We can also use our technology ...

Keros Therapeutics said on Thursday it had paused giving patients higher doses of its high blood pressure treatment in a ...

Keros Therapeutics (NASDAQ:KROS) stock plunged 73% Thursday after the company said it has halted two arms of a Phase 2 ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.